Citations

Showing 10 of 108094 citations.

Primary care physicians’ perceptions of practice improvement as a professional responsibility: a cross-sectional study
Stephenson, Christopher R. , Wittich, Christopher M. , Pacyna, Joel E. , Wynia, Matthew K., Tilburt, Jon C. , Hasan, Omar

Mayo Clinic

Medical Education Online | May 17, 2018 | Volume: 23 | Issue: 1 | Pages: 1474700

10.1080/10872981.2018.1474700 | PMID 29768977 Get It

Learning From Failure in Cartilage Repair Surgery: An Analysis of the Mode of Failure of Primary Procedures in Consecutive Cases at a Tertiary Referral Center
Krych, Aaron J. , Desai, Vishal S. , Saris, Daniël B.F. , Krych, Aaron J , Hevesi, Mario , Desai, Vishal , Camp, Christopher L. , Stuart, Michael J.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | May 17, 2018 | Volume: 6 | Issue: 5 | Pages: No page available

10.1177/2325967118773041 | PMID 29796401 Get It

Background: As the number of cartilage restoration procedures is increasing, so is the number of revision procedures. However, there remains limited information on the reasons for failure of primary cartilage restoration procedures. Purpose: To determine the common modes of failure in primary cartilage restoration procedures to improve surgical decision making and patient outcomes. Study Design: Case series; Level of evidence, 4. Methods: Patients who presented for revision after failed cartilage repair surgery were evaluated for factors contributing to failure of the primary procedure. All revision cases performed by a single surgeon at a tertiary center for failed cartilage restoration over a 6-year time frame were identified. In all cases, the medical records, preoperative radiographs, and magnetic resonance imaging scans were reviewed by 2 experienced cartilage surgeons. The cause for failure was categorized as malalignment, meniscal deficiency, graft or biologic failure, or instability. Univariate and descriptive statistics regarding patient demographics, index procedure, lesion location and size, and mechanism of failure were analyzed. Results: A total of 59 cases in 53 patients (32 male, 21 female) met the inclusion criteria. The mean patient age at the time of revision was 27.6 years, and the mean body mass index was 28.4 kg/m 2 . Failed index surgical procedures included 35 microfractures (59%), 12 osteochondral allograft transplantations (20%), 10 osteochondral autograft transfers (17%), 2 nonviable osteochondral allografts (3%), and 2 particulated juvenile chondral allografts (3%). The mean lesion size was 4.4 cm 2 . Reasons for failure included 33 cases with untreated malalignment (56%), 16 with graft failure (27%), 11 with untreated meniscal deficiency (19%), and 3 with untreated instability (5%); 4 cases demonstrated multiple reasons for failure. Conclusion: The most commonly recognized reason for failure was untreated malalignment. While biologic and graft failures will occur, the majority of failures were attributed to untreated background factors such as malalignment, meniscal deficiency, and instability. The stepwise approach of considering and addressing alignment, meniscal volume, and stability remains essential in cartilage restoration surgery.
Whole‐exome sequencing for variant discovery in blepharospasm
Tian, Jun , Vemula, Satya R. , Xiao, Jianfeng , Defazio, Giovanni , Petrucci, Simona , Gigante, Angelo Fabio , Rudzińska, Monika , Kennelly, Kathleen D., Uitti, Ryan J. , Gerpen, Jay A. van, Hedera, Peter , Trimble, Elizabeth J. , LeDoux, Mark S. , Van Gerpen, Jay A, LeDoux, Mark S , Rudzinska-Bar, Monika , Valente, Enza Maria , Wszołek, Zbigniew K.

Mayo Clinic

Molecular Genetics & Genomic Medicine | May 17, 2018 | Volume: 6 | Issue: 4 | Pages: 601-626

10.1002/mgg3.411 | PMID 29770609 Get It

AbstractBackgroundBlepharospasm (BSP) is a type of focal dystonia characterized by involuntary orbicularis oculi spasms that are usually bilateral, synchronous, and symmetrical. Despite strong evidence for genetic contributions to BSP, progress in the field has been constrained by small cohorts, incomplete penetrance, and late age of onset. Although several genetic etiologies for dystonia have been identified through whole‐exome sequencing (WES), none of these are characteristically associated with BSP as a singular or predominant manifestation.MethodsWe performed WES on 31 subjects from 21 independent pedigrees with BSP. The strongest candidate sequence variants derived from in silico analyses were confirmed with bidirectional Sanger sequencing and subjected to cosegregation analysis.ResultsCosegregating deleterious variants (GRCH37/hg19) in CACNA1A (NM_001127222.1: c.7261_7262delinsGT, p.Pro2421Val), REEP4 (NM_025232.3: c.109C>T, p.Arg37Trp), TOR2A (NM_130459.3: c.568C>T, p.Arg190Cys), and ATP2A3 (NM_005173.3: c.1966C>T, p.Arg656Cys) were identified in four independent multigenerational pedigrees. Deleterious variants in HS1BP3 (NM_022460.3: c.94C>A, p.Gly32Cys) and GNA14 (NM_004297.3: c.989_990del, p.Thr330ArgfsTer67) were identified in a father and son with segmental cranio‐cervical dystonia first manifest as BSP. Deleterious variants in DNAH17, TRPV4, CAPN11, VPS13C, UNC13B, SPTBN4, MYOD1, and MRPL15 were found in two or more independent pedigrees. To our knowledge, none of these genes have previously been associated with isolated BSP, although other CACNA1A mutations have been associated with both positive and negative motor disorders including ataxia, episodic ataxia, hemiplegic migraine, and dystonia.ConclusionsOur WES datasets provide a platform for future studies of BSP genetics which will demand careful consideration of incomplete penetrance, pleiotropy, population stratification, and oligogenic inheritance patterns.
Lower Extremity Limb Salvage with Cross Leg Pedicle Flap, Cross Leg Free Flap, and Cross Leg Vascular Cable Bridge Flap
Manrique, Oscar J. , Bishop, Sarah N. , Ciudad, Pedro , Adabi, Kian , Martinez‐Jorge, Jorys, Moran, Steven L. , Huang, Tony Chieh‐Ting , Vijayasekaran, Aparna , Huang, Tony, Huang, Tony C T , Chen, Shih‐Heng , Chen, Hung‐Chi

Mayo Clinic

Journal of Reconstructive Microsurgery | May 16, 2018 | Volume: 34 | Issue: 07 | Pages: 522-529

10.1055/s-0038-1641712 | PMID 29768632 Get It

Background Lower extremity salvage following significant soft tissue loss can be complicated by lack of recipient vessel for free tissue transfer. We describe our experience in lower limb salvage for patients with no recipient vessels with the use of pedicle, free and cable bridge flaps. Methods A retrospective review from 1985 to 2017 of patients undergoing lower limb salvage using a contralateral pedicle cross leg (PCL) flaps, free cross leg (FCL) flaps, or free cable bridge (FCB) flaps was conducted. Demographics, etiology of the reconstruction, type of flap used, donor-site vessels, defect size, operating time, time of pedicle division, length of hospital stay, time to ambulation, and complications were analyzed. Results A total of 53 patients (48 males and 5 females) with an average age of 35 years (range, 29–38 years) were identified. The etiology for the reconstruction was trauma in 52 patients and oncological resection in 1 patient. There were 18 PCL, 25 FCL, and 10 FCB completed. The recipient vessels for all flaps were the posterior tibial artery and vein. The average operating room times for PCL, FCL, and FCB flaps were 4, 9, and 10 hours, respectively. The average length of hospital stay was 5 weeks and average time to ambulation was 4 weeks. The average follow-up time was 7.5 years (range, 3–12 years). Complications encountered were hematoma (six), prolonged pain (six), total flap loss (two), reoperation (five), and infection (four). Limb salvage rates were 96.2%. Conclusion When ipsilateral limb vessels are not available, and other reconstructive options have been exhausted, cross leg flaps can be a viable option for limb salvage in the setting of extensive defects.
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Shroff, Rachna T. , Hendifar, Andrew , Geva, Ravit , Epelbaum, Ron, Rolfe, Lindsey, Goble, Sandra, Giordano, Heidi, Vonderheide, Robert H. , Lin, Kevin K. , McWilliams, Robert R. , Lin, Kevin , Biankin, Andrew V. , Domchek, Susan M.

Mayo Clinic

JCO Precision Oncology | May 16, 2018 | Volume: No volume available | Issue: 2 | Pages: 1-15

10.1200/po.17.00316 | PMID 30051098 Get It

Purpose Pancreatic cancer has a poor prognosis and limited treatment options. Approximately 9% of pancreatic cancers harbor a germline or somatic BRCA1 or BRCA2 ( BRCA1/2) mutation. Because poly (ADP-ribose) polymerase inhibitors have significant activity in BRCA1/2-mutant ovarian and breast cancers, RUCAPANC investigated the efficacy and safety of rucaparib in BRCA1/2-mutant pancreatic cancer. Patients and Methods RUCAPANC enrolled patients with measurable locally advanced/metastatic pancreatic cancer who had received one to two prior chemotherapy regimens. Patients received oral rucaparib (600 mg twice daily) until disease progression. The primary end point was objective response rate. Results Nineteen patients were enrolled. Sixteen of 19 BRCA1/2 mutations were germline; three were somatic. Patients had received a median of two prior chemotherapy regimens. Four patients achieved a response; two partial responses and one complete response (CR) were confirmed (objective response rate, 15.8%; 3 of 19), with an additional CR unconfirmed. The disease control rate (CR, partial response, or stable disease for ≥ 12 weeks) was 31.6% (6 of 19) in all patients and 44.4% (4 of 9) in those who had received one prior chemotherapy regimen. As prespecified in the protocol, enrollment was stopped because of an insufficient response rate among the first 15 patients. Treatment-emergent adverse events included nausea (63.2%) and anemia (47.4%). Grade ≥ 3 adverse events included anemia (31.6%), fatigue (15.8%), and ascites (15.8%). Secondary resistance mutations were detected in circulating free tumor DNA in two patients with a germline BRCA2 mutation. These mutations are predicted to lead to the reversion of a somatic—not germline—mutation. Conclusion Rucaparib provided clinical benefit to patients with advanced pancreatic cancer and a BRCA1/2 mutation, and demonstrated an acceptable safety profile. Additional trials of rucaparib in this population are warranted.
Baseline Thromboelastogram as a Predictor of Left Ventricular Assist Device Thrombosis
Piche, Shannon L., Nei, Scott D. , Frazee, Erin, Schettle, Sarah , Boilson, Barry A. , Plevak, Matthew F., Dierkhising, Ross , Stulak, John M., Schettle, Sarah D., Dierkhising, Ross A, Frazee, Erin

Mayo Clinic

ASAIO Journal | May 16, 2018 | Volume: 65 | Issue: 5 | Pages: 443-448

10.1097/mat.0000000000000828 | PMID 29768282 Get It

Left ventricular assist device (LVAD) pump thrombosis occurs in up to 8.4% of patients within 3-months postimplantation. Thromboelastography (TEG) could be used to signal hypercoagulability at LVAD implantation to predict patients at high risk for thrombosis. We sought to evaluate whether TEG maximum amplitude (MA) hypercoagulability (MA ≥69 mm) at the time of LVAD implantation predicts pump thrombosis. A single center, retrospective, nested case–control study was conducted using patients from January 1, 2005, to March 31, 2015. Each pump thrombosis case was matched to two control subjects based on age ± 5 years, sex, and duration of follow-up. A multivariable logistic regression analysis was performed on the matched sets; the odds ratio with 95% confidence interval (CI) was calculated to estimate the relative risk. Thirty-seven age- and sex-matched case–control sets were included for a total of 111 study participants. TEG-MA hypercoagulability occurred in 10.8% of the case group versus 6.8% of controls. There was no association between TEG-MA hypercoagulability and device thrombosis (odds ratio 1.71, 95% confidence interval 0.42–7.05, p = 0.46). Utilization of baseline TEG-MA hypercoagulability to detect individuals at risk for LVAD thrombosis is a novel concept. This study found no significant association between TEG-MA and LVAD thrombosis.
Long-Term Outcomes of Pedicled Gastrocnemius Flaps in Total Knee Arthroplasty
Wagner, Eric R. , Harmsen, William S. , Hanssen, Arlen D. , Taunton, Michael J. , Moran, Steven L. , Wyles, Cody C. , Wagner, Eric R , Taunton, Michael J , Houdek, Matthew T.

Mayo Clinic

Journal of Bone and Joint Surgery | May 16, 2018 | Volume: 100 | Issue: 10 | Pages: 850-856

10.2106/jbjs.17.00156 | PMID 29762280 Get It

Background: Deficient soft tissue following total knee arthroplasty (TKA) can jeopardize outcome. The gastrocnemius flap is an important means of providing coverage of a knee with deficient soft tissue. There is a paucity of long-term studies on the use of the gastrocnemius flap in the setting of TKA. The purpose of this study was to review the outcomes after the use of pedicled gastrocnemius flaps for coverage of a soft-tissue defect at the time of TKA. Methods: Eighty-three patients in whom a gastrocnemius flap had been used to cover the site of a primary (n = 18) or revision (n = 65) TKA over a 25-year period were identified. There were 48 women (58%) and 35 men (42%) with a mean age and body mass index (BMI) of 65 years and 32.6 kg/m 2 . The mean wound size was 49 cm 2 , and the wound was most commonly located over the anterior aspect of the knee/patellar tendon (n = 33). Patients were followed to the time of implant or flap revision, amputation, or death or for a minimum of 2 years (mean, 8 years). Clinical outcomes were assessed using the Knee Society Score (KSS) for pain and the KSS for function. The Kaplan-Meier method was used to assess revision and amputation-free survival. Risk factors for amputation and revision were identified with Cox regression. Results: The 10-year revision and amputation-free survival rates following gastrocnemius flap coverage were 68% and 79%, respectively. The risk of implant failure was increased by morbid obesity (BMI of ≥40 kg/m 2 ) (hazard ratio [HR] = 2.82, 95% confidence interval [CI] = 1.09 to 7.32, p = 0.03) and ≥5 prior surgical procedures on the knee (HR = 2.68, 95% CI = 1.04 to 6.88, p = 0.04). The risk of amputation was increased in patients with ≥5 prior surgical procedures (HR = 10.76, 95% CI = 2.38 to 48.58, p = 0.002), an age of ≥65 years (HR = 4.94, 95% CI = 1.10 to 22.09, p = 0.03), and a wound size of ≥50 cm 2 (HR = 3.29, 95% CI = 1.14 to 9.53, p = 0.02). Preoperatively the mean KSSs for pain and function were 46 and 28, and these scores significantly (p < 0.05) improved to 78 and 43, respectively, at the time of follow-up. Conclusions: The gastrocnemius flap reliably provides coverage of components used in complex knee reconstruction. A history of multiple surgical procedures on the knee and larger soft-tissue defects increase the risk of revision TKA and of amputation. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.
A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome
Clot, Guillem , Jares, Pedro , Giné, Eva , Navarro, Alba , Pinyol, Magda, Martin‐García, David , Demajo, Santiago , Espinet, Blanca , Salar, Antonio , Ferrer, Ana , Muntañola, Ana , Aymerich, Marta , Rauert‐Wunderlich, Hilka , Gascoyne, Randy D. , Delabie, Jan , López‐Guillermo, Armando , Ott, German , Wright, George W. , Staudt, Louis M. , Rosenwald, Andreas , Beà, Sı́lvia , Martín-Garcia, David , Demajo, Santiago , Salar, Antonio , Ferrer, Ana , Jaffe, Elaine S , Connors, Joseph M , Delabie, Jan , López-Guillermo, Armando , Beà, Sílvia , Campo, Elías , Royo, Cristina , Jaffe, Elaine S. , Connors, Joseph M. , Scott, David W. , Rimsza, Lisa M. , Campo, Elı́as , Espinet, Blanca , Wright, George

Mayo Clinic

Blood | May 16, 2018 | Volume: 132 | Issue: 4 | Pages: 413-422

10.1182/blood-2018-03-838136 | PMID 29769262 Get It

Key PointsA new molecular assay identifies conventional and leukemic nonnodal MCL with differing clinicobiological features. The integration of the novel assay with genetic alterations identifies subsets of MCL patients with different management and outcome.
Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma
Yoon, Harry H. , Karapetyan, Lilit , Choudhary, Anita , Kosozi, Ramla, Bali, Gurvinder Singh, Atasoy, Ajlan, Forastiere, Arlene A. , Gibson, Michael K. , Yoon, Harry, Gibson, Michael K , Zaidi, Ali Hussainy

Mayo Clinic

The Oncologist | May 16, 2018 | Volume: 23 | Issue: 9 | Pages: 1004-e102

10.1634/theoncologist.2017-0657 | PMID 29769385 Get It

Abstract Lesson Learned Panitumumab plus irinotecan is not active for the treatment of esophageal adenocarcinoma. Background Esophageal adenocarcinoma (EAC) is a lethal cancer with increasing incidence. Panitumumab (Pa) is a fully humanized IgG2 monoclonal antibody against human EGFR. Cetuximab (Cx) combined with irinotecan (Ir) is active for second-line treatment of colorectal cancer. This phase II study was designed to evaluate Pa plus Ir as second-line therapy for advanced EAC. Methods The primary endpoint was response rate (RR). Patients with one prior treatment were given Pa 9 mg/m2 on day 1 and Ir 125 mg/m2 on days 1 and 8 of each 21-day cycle. Inclusion criteria were confirmed EAC, measurable disease, no prior Ir or Pa, performance status &lt;2, and normal organ function. Results Twenty-four patients were enrolled; 18 were eligible and evaluable. These patients were all white, with a median age of 62.5 years (range, 33–79 years), and included 15 men and 3 women. The median number of cycles was 3.5. The most common grade 1–2 adverse events were fatigue, diarrhea, anemia, leukopenia, and hypoalbuminemia. Grade 3–4 adverse events included hematologic, gastrointestinal, electrolyte, rash, fatigue, and weight loss. The median follow-up was 7.2 months (range, 2.3–14 months). There were no complete remissions. The partial response rate was 6% (1/18; 95% confidence interval [CI], 0.01–0.26). The clinical benefit (partial response [PR] plus stable disease [SD]) rate was 50%. The median overall survival was 7.2 months (95% CI, 4.1–8.9) with an 11.1% 1-year survival rate. The median progression-free survival was 2.9 months (95% CI, 1.6–5.3). Conclusion Irinotecan and panitumumab as second-line treatment for advanced EAC are not active.
Getting Hit by Pitch in Professional Baseball: Analysis of Injury Patterns, Risk Factors, Concussions, and Days Missed for Batters
Sinatro, Alec S., D’Angelo, John, Coleman, Struan H. , Fealy, Stephen, Conte, Stan, Camp, Christopher L. , Wang, Dean , Dines, Joshua S.

Mayo Clinic

The American Journal of Sports Medicine | May 16, 2018 | Volume: 46 | Issue: 8 | Pages: 1997-2003

10.1177/0363546518773048 | PMID 29768041 Get It

Background: Although batters are frequently hit by pitch (HBP) in baseball, the effect of HBP injuries remains undefined in the literature. Purpose: To determine the effect of HBP injuries in terms of time out of play, injury patterns resulting in the greatest time out of play, and the value of protective gear such as helmets and elbow pads. Study Design: Descriptive laboratory study. Methods: Based on the Major League Baseball (MLB) Health and Injury Tracking System, all injuries to batters HBP during the 2011-2015 MLB and Minor League Baseball (MiLB) seasons were identified and analyzed. Video analysis was performed on all HBP events from the 2015 MLB season. Multivariate stepwise regression analysis was utilized to determine the predictive capacity of multiple variables (velocity, pitch type, location, etc) on injury status and severity. Results: A total of 2920 HBP injuries resulted in 24,624 days missed (DM) over the 5 seasons. MLB HBP injuries occurred at a rate of 1 per 2554 plate appearances (1 per 9780 pitches thrown). Mean DM per injury were 8.4 (11.7 for MLB vs 8.0 for MiLB, P < .001). Surgery was required for 3.1% of MLB injuries and 1.2% of MiLB injuries ( P = .005). The most common body regions injured were the hand/fingers (n = 638, 21.8%), head/face (n = 497, 17.0%), and elbow (n = 440, 15.7%), and there were 146 (5.0%) concussions. Injury rates and mean DM correlated with velocity in a near linear fashion. Players hit in the head/face (odds ratio, 28.7) or distal upper extremity (odds ratio, 6.4) were more likely to be injured than players HBP in other locations. Players with an unprotected elbow missed 1.7 more days (95% CI, –4.1 to 7.6) than those with an elbow protector ( P = .554) when injured after being HBP. Conclusion/Clinical Relevance: Although HBP injuries occur infrequently in the course of normal play, they collectively represent a significant source of time out of play. The most common body regions injured include the hands/fingers and head/face, and batters hit in these locations are significantly more likely to be injured. After contusions, concussions were the most common injury diagnosis.